Is Randox Laboratories profitable in 2026?

No. FY2025 accounts filed July 2026 show turnover of £190m, up 8%, but a pre-tax loss of roughly £17.3m to £24m depending on reporting entity, marking a third straight year of losses totaling about £115.5m since the 2022 pandemic-testing peak.

Is Randox laying off staff?

Yes. Average headcount fell from 2,314 in FY2024 to 1,926 in FY2025, a cut of about 388 people (17%), concentrated in R&D roles, per accounts filed with Companies House and reported July 2026.

Could AI replace Randox's diagnostic tests?

Unlikely for the core product. Randox's patented Biochip Array Technology is a physical wet-lab multiplex assay covering 12,000+ targets that requires sample processing; AI exposure is limited to the consumer interpretation layer, like RanChip Insight 360 launched June 2026.

Who owns Randox Laboratories?

Randox is privately owned by founder Dr Peter FitzGerald, who started the company in 1982. In March 2020 it was restructured under an Isle of Man holding entity, Randox (IOM) Ltd, reportedly for generational ownership transfer planning; there is no public listing or disclosed VC funding.

Who is Randox's biggest competitor?

Roche Diagnostics, Abbott, Siemens Healthineers, Thermo Fisher and Danaher dominate the global IVD market Randox competes in; Roche alone held roughly 20% global IVD share as of mid-2026 and spent about £15B on R&D in 2023, dwarfing Randox's budget.

What was the Randox forensic toxicology scandal?

A 2017 data-manipulation case at Randox's forensic toxicology labs implicated roughly 10,500 cases and up to 1,277 convictions; Greater Manchester Police's multi-year investigation was still generating Freedom of Information disputes as of January 2025.

Biotech tools companies · United Kingdom

Randox Laboratories Ltd

randox.com ↗

UK maker of multiplex biochip diagnostic tests and Randox Health consumer clinics.

Losing its protection

Assessed 24 July 2026 · Evidence as of 24 July 2026

The structural protection is eroding.

On the recordSince 24 July 2026 · Checkable from mid-2027 · Every call on the record Checkpoint: FY2026 accounts filing, showing whether 8% revenue growth turns into profit or a fourth straight loss year

The call

Randox has cash and patented lab technology to survive, but three straight loss years and R&D cuts show the pandemic-era profit surge has not been replaced.

Randox Laboratories makes medical testing equipment with a special chip that can run many tests at once. The company has been around for 44 years and has thousands of machines installed in labs worldwide, which is hard for competitors to replace quickly. However, Randox has lost money for three years straight, just fired research workers, and faces giants like Roche and Abbott that spend 50 to 300 times more on research and development, meaning those companies move faster on new technology and can buy up smaller competitors. The big question is whether Randox can get back to making money by 2026 and whether it will keep investing in research or keep cutting costs, because if cutting costs becomes the main strategy, the company could fall further behind.

Why

AI pressure: Generic AI health-interpretation apps. AI apps could commoditize the results-interpretation layer around Randox Health tests, but not the wet-lab biochip assay itself. Could AI do the core job? Unlikely.

Bigger players: Roche Diagnostics, Abbott, Siemens Healthineers, Thermo Fisher Scientific, Danaher. These rivals already sell competing multiplex and AI-assisted diagnostics platforms while outspending Randox on R&D by 50 to 300 times. Could a giant copy it? Probably.

What protects it. Patented multiplex biochip technology, regulatory certifications, and a 100,000-plus lab installed base make switching costly for customers.

What would change this call

Randox FY2026 accounts filing due mid-2027 show a fourth straight annual loss. Would show the margin squeeze from larger rivals is structural, not one-time.
Randox R&D headcount continues falling below the FY2025 level of 1,926 average staff. Would show the 17% cut was the start of sustained R&D erosion, not right-sizing.
Abbott, Roche or Siemens launch a competing multiplex or AI-CDx diagnostics product targeting Randox's biochip niche. Would show larger rivals directly contesting Randox's core patented product line.

Key numbers

FY2025 turnover £190m, up 8% year on year (2026-07-07)
Three year cumulative losses of £115.5m (2026-07-07)
Average headcount cut 17%, down 388 to 1,926 (2026-07-07)

Named risks

Three consecutive years of losses totaling ~£115.5m through FY2025 despite revenue growth. Severity: high
17% R&D headcount cut in FY2025 could be start of structural margin erosion rather than one-off right-sizing. Severity: medium
Unresolved 2017 forensic toxicology data-manipulation scandal affecting up to 1,277 convictions. Severity: medium
Political scrutiny of COVID-era contracts resurfacing in UK Covid-19 Inquiry testimony (March 2025). Severity: low
Giants like Roche and Abbott outspending and consolidating faster in AI-native diagnostics. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Roche Diagnostics	gaining on	~20% global IVD share mid-2026, ~£15B R&D spend in 2023 vs Randox's much smaller budget
Abbott	gaining on	Announced acquisition of Exact Sciences in March 2026, consolidating IVD market
Siemens Healthineers, Thermo Fisher, Danaher	contesting	Collectively outspend Randox in R&D by an estimated 50 to 300 times as of 2026
Bio-Rad, Sysmex, bioMerieux	contesting	Named alongside Randox as direct peers in biochemistry analyzer and clinical chemistry market reports

Questions people ask

Is Randox Laboratories profitable in 2026?: No. FY2025 accounts filed July 2026 show turnover of £190m, up 8%, but a pre-tax loss of roughly £17.3m to £24m depending on reporting entity, marking a third straight year of losses totaling about £115.5m since the 2022 pandemic-testing peak.
Is Randox laying off staff?: Yes. Average headcount fell from 2,314 in FY2024 to 1,926 in FY2025, a cut of about 388 people (17%), concentrated in R&D roles, per accounts filed with Companies House and reported July 2026.
Could AI replace Randox's diagnostic tests?: Unlikely for the core product. Randox's patented Biochip Array Technology is a physical wet-lab multiplex assay covering 12,000+ targets that requires sample processing; AI exposure is limited to the consumer interpretation layer, like RanChip Insight 360 launched June 2026.
Who owns Randox Laboratories?: Randox is privately owned by founder Dr Peter FitzGerald, who started the company in 1982. In March 2020 it was restructured under an Isle of Man holding entity, Randox (IOM) Ltd, reportedly for generational ownership transfer planning; there is no public listing or disclosed VC funding.
Who is Randox's biggest competitor?: Roche Diagnostics, Abbott, Siemens Healthineers, Thermo Fisher and Danaher dominate the global IVD market Randox competes in; Roche alone held roughly 20% global IVD share as of mid-2026 and spent about £15B on R&D in 2023, dwarfing Randox's budget.
What was the Randox forensic toxicology scandal?: A 2017 data-manipulation case at Randox's forensic toxicology labs implicated roughly 10,500 cases and up to 1,277 convictions; Greater Manchester Police's multi-year investigation was still generating Freedom of Information disputes as of January 2025.

Timeline

2026-07-11Irish Times reports R&D headcount cuts described as post-Covid realignment
2026-07-07FY2025 accounts filed showing £190m turnover, loss, and 17% headcount cut
2026-06-05Randox Health launches RanChip Insight 360 AI-linked biomarker product
2026-03Abbott announces acquisition of Exact Sciences, intensifying IVD consolidation
2025-11-03Randox announces cumulative sales passed £1 billion since inception
2025-09-05Jefferson County, West Virginia site converted to full manufacturing plant
2025-03-19UK Covid-19 Inquiry testimony revisits Owen Paterson's Randox lobbying links
2022-04Randox buys Boston House, Fitzroy Square, London for £29m education centre
2020-03Corporate restructure moves ownership to Isle of Man holding entity
1982-04Randox founded by Dr Peter FitzGerald in County Antrim

Revision history

24 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Element Biosciences Charles River Laboratories Bio-Techne Corporation